Off-patent drug sector stakeholders have expressed concerns about the impact of rising inflation on the generic and biosimilar industries going forward into 2023, with some calling for interventions from national authorities to preserve the stability of the space.
Of 29 countries with comparable inflation figures selected by the UK Office of National Statistics – including 26 of the...



